已推出眼科手术机器人和显微外科手术机器人等产品。 本文为IPO早知道原创 作者｜ C叔 微信公众号｜ipozaozhidao 据IPO早知道消息，近日，杭州迪视医疗生物科技有限公司（下称"迪视医疗"）完成数千万元A2轮 融资，由达晨财智领投，磐霖资本持续追加投资，凯乘资本持续担任独家财务顾问。本轮资金将加快 推动迪视医疗超显微手术机器人从技术领先走向市场普及。 迪视医疗以机器人显微操作为核心技术，长期深耕超显微手术机器人细分赛道，超显微机器人相关产 品能够突破人手操作极限，解决医生操作痛点，是解决大量"未被满足的临床需求"的关键钥匙，该 领域也是手术机器人领域下一个蓝海市场。迪视医疗不仅在技术性和临床进度上领跑国内赛道，更重 要的是，真正站在患者的角度，从临床需求出发研发出了高技术壁垒的眼科和显微外科机器人产品， 突破了医生"看得到办不到"的难点，极具巨大社会价值。 突破"人手极限"：为数千万患者开启复明与康复之窗 作为专注于超显微手术机器人产品研发企业，迪视医疗自成立以来始终秉持以临床超显微手术需求为 导向的初衷，致力于 通过机器人辅助技术，滤除人手抖动，实现微米级的精准操作。 在眼科领域， 中国拥有超过4 ...

近日， 杭州迪视医疗生物科技有限公司 （简称" 迪视医疗 "）完成 数千万元A2轮融资 。本轮融资由 达 晨财智领投，老股东磐霖资本持续追加 。这距离公司完成上一轮由磐霖资本领投的融资时隔仅半年时间。 该笔资金将加快推动迪视医疗超显微手术机器人从技术领先走向市场普及。 作为短时间内连续支持迪视医疗的投资方，磐霖资本持续看好超显微手术机器人这个细分赛道。 磐霖医疗 器械投资团队 认为，超显微机器人相关产品能够突破人手操作极限，解决医生操作痛点，是 解决大量"未 被满足的临床需求"的关键钥匙 ，该领域也是手术机器人领域下一个蓝海市场。迪视医疗不仅在技术性和 临床进度上领跑国内赛道，更重要的是，他们真正站在患者的角度，从临床需求出发研发出了高技术壁垒 的眼科和显微外科机器人产品，突破了医生"看得到办不到"的难点，极具巨大社会价值。 突破"人手极限"： 为数千万患者开启复明与康复之窗 在显微外科领域，0.1-0.6毫米的微细血管、淋巴管及神经吻合一直是医学界的"巅峰挑战"。 传统的纯人 手操作受限于生理性震颤，使得许多极高难度的术式难以大规模普及。 作为专注于 超显微手术机器人产品研发企业， 迪视医疗自成立以来，始终 ...

产业发展不仅需要"资本输血"，更需要"服务造血"。为了给人工智能企业提供更加优质、高效的服 务，上城资本集团还设计分级服务体系，根据企业不同发展阶段、规模体量及核心需求，量身定制包含 政策对接、融资支持、市场拓展等要素的专属服务资源包，提供精准化、差异化、全生命周期的服务支 持。日前，杭港科技大厦为企服务中心（元宇宙产业增值服务驿站）不断丰富服务事项，整合联动优势 资源，旨在为企业提供更加便捷、高效的"一站式"政务服务，持续优化营商环境、赋能企业发展。 作为上城区人工智能与医疗科技融合创新的典型代表，迪视医疗的突破式发展离不开上城资本集团 的深度赋能——日前，迪视医疗完成近亿元A轮融资，其中上城资本是重要的投资方。 接下来，上城资本集团将紧紧围绕上城区建设中央创新区（CID）的战略部署，加快融入"黄金左 岸"人工智能产业带及具身智能创新生态圈，推动未来产业资源导入与产业集群培育，促进产业链创新 链深度融合，努力构建"上下楼即上下游"的协同生态。 显微镜前，研发人员凝神专注，操控着两只机械臂，在发丝般纤细的仿真血管上精准"穿针引线"。 随着机械臂流畅完成移动、套接与吻合动作，断开的血管实现"无缝衔接"——这一幕 ...

Group 1 - The youngest female billionaire in the world, Lucy Guo, emerged at the age of 30 after Meta's investment of approximately $15 billion in Scale AI, raising the company's valuation to $29 billion [1] - Scale AI, founded in 2016 by two young Chinese entrepreneurs, provides data labeling services for artificial intelligence, capitalizing on the growing demand for AI technologies [1] Group 2 - Goldman Sachs is raising its largest-ever S fund, targeting over $14.2 billion, coinciding with significant fundraising activities from other major firms like Blackstone and Apollo [2] - Blackstone recently executed a $5 billion S transaction, indicating a competitive environment for S fund investments [2] Group 3 - NIO's associated company, Hezhong New Energy, has entered bankruptcy reorganization, with the case being updated on the national bankruptcy reorganization information website [3] - The bankruptcy case was initiated by Shanghai Yuxing Advertising Co., indicating potential challenges for NIO in the electric vehicle market [3] Group 4 - CSPC Pharmaceutical Group has entered into a collaboration with AstraZeneca worth over $5 billion, which includes an upfront payment of $110 million and potential milestone payments totaling up to $1.62 billion [3] - The deal also includes potential sales milestone payments of up to $3.6 billion, showcasing CSPC's strategic growth in the pharmaceutical sector [3] Group 5 - Pop Mart's newly opened store in Hangzhou was forced to close shortly after opening due to internal issues, while its first jewelry brand store, "popop," opened in Beijing [3] - This move reflects Pop Mart's diversification strategy into the jewelry market, aiming to expand its business portfolio [3] Group 6 - The film "Nezha 2" has grossed over 15.8 billion yuan globally, with the production company potentially receiving around 5.2 billion yuan based on current revenue-sharing rules [3] - The chairman of the production company suggested a need to adjust the profit-sharing model in the Chinese film industry to ensure sustainable investment in filmmaking [3] Group 7 - Dvision Medical completed nearly 100 million yuan in Series A financing, with the funds aimed at accelerating the registration and commercialization of surgical robots [6] - The investment was led by Panlin Capital, indicating strong interest in innovative medical technologies [6] Group 8 - Meichuang Medical secured a significant equity financing round, with participation from various investors, focusing on developing peripheral vascular and tumor intervention products [7] - The company aims to leverage the founder's extensive industry experience to enhance its market position [7] Group 9 - Xinyuan New Materials completed a Series C financing round, with exclusive investment from Xiaomi's equity investment fund, focusing on the development of silicon carbide packaging materials [8] - This funding marks a significant step for the company in the third-generation semiconductor materials sector [8]